CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old (NCT04269213)
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Who can join: Review the eligibility criteria below.
Location: University of Nebraska Medical Center — Omaha, Nebraska
Age range: 18 Years to 59 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- University of Nebraska Medical Center — Omaha, Nebraska
- Roswell Park Cancer Institute — Buffalo, New York
- SUNY Upstate Medical Center — Syracuse, New York
- Allegheny Health Network Cancer Institute - West Penn Hospital — Pittsburgh, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Hu8F4 in Treating Patients With Advanced Hematologic Malignancies — Augusta, Georgia
- Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia — Tucson, Arizona
- Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — Columbus, Ohio
Explore by condition: All Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.